For immediate release 10 December 2016

Commencement of Strategic Cooperation by CEO of Intuitive Surgical, a Global Leader in the Field of Robotic-Assisted Minimally Invasive Surgery, with Fosun Pharma

【December 10 2016, Hong Kong】On the morning of 10 December 2016, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH, 02196.HK) held Fosun Pharma & Intuitive Surgical, Inc. Strategic Cooperation Press Conference and Artificial Intelligence-assisted Precision Medicine Summit at Shanghai Ruijin Hotel. Witnessed by Huang Hong, Secretary of Party Committee of Shanghai Municipal Commission of Health and Family Planning, Xulai, Deputy Director General of Shanghai Food and Drug Administration, Zhao Zilin, Chairman of China Association of Medical Equipment, Wang Longxing, Chairman of Shanghai Pharmaceutical Association and Guo Guangchang, Chairman of Fosun Group and Non-executive Director of Fosun Pharma, Chen Qiyu, Chairman of Fosun Pharma and Dr. Gary Guthart, President and Chief Executive Officer of Intuitive Surgical, Inc. (hereinafter referred to as "Intuitive Surgical") announced on site the official commencement of their strategic cooperation in China. The two parties will jointly invest US100 million to establish a joint venture in Shanghai, which will mainly engage in research, production and sale of innovative robotic-assisted catheter-based technology for early-stage diagnosis and treatment of lung cancer. This will be a new product line separate from the da Vinci(R) Surgical System products developed by Intuitive Surgical.

"Chindex Medical Limited, a holding subsidiary of Fosun Pharma, is a distribution partner for Intuitive Surgical's da Vinci Surgical Systems in China. Our collaboration with Fosun Pharma started in 2011, and we are proud to be expanding our relationship to explore new and innovative healthcare solutions together," said Dr. Gary Guthart, President and CEO of Intuitive Surgical. "It is the first time we are establishing a R&D and production center in China. We are looking forward to making this important long-term commitment to China."

The joint venture will be engaging in the development of medical tools for diagnosis and treatment of lung cancer, both domestically and internationally, in a more convenient, efficient and comfortable way with its motto of "domestic manufacture, joint R&D and global sales". Initial product developments will be applicable to the early diagnosis of lung cancer, and whereas R&D work at a later stage will be focused on early and effective treatment of lung cancer.

Currently, lung cancer in China has a mortality rate that is ranked first among all kinds of cancer. Lung cancer is also recognized as the top killer among all cancers globally, with one of five fatal cancer cases being lung cancer.

Chen Qiyu, Chairman of Fosun Pharma, mentioned that "Lung cancer is one of the most common cancers in the world, particularly in China, so the early diagnosis and treatment are extremely important. Intuitive Surgical is a great company driven by cutting-edge technology. We hope that the costs on diagnosis and treatment of Chinese patients suffering from lung cancer would be reduced through the localization of R&D, manufacture and sales by establishing the joint venture company with Intuitive Surgical. We expect that the cooperation will allow doctors to be equipped with innovative medical tools for precise diagnosis in order to upgrade the standard of medical treatment. We're confident that the innovative products developed by the new joint venture will be marked to China rapidly, and then further benefit patients across the globe. "

Mr. Guo Guangchang said, "Since the very beginning of Fosun Group's establishment, pharmaceutical and healthcare have been one of our key segments. After developing for more than 20 years, Fosun healthcare sector is now a leader in China's pharmaceutical and healthcare industry. Healthcare is a crucial cog for Fosun's strategy of focusing on demand for wealth, health and happiness from middle-class families. Since precision medicine is the future direction of healthcare industry, we hope that we can integrate the cutting-edge R&D capabilities of Intuitive Surgical with the extensive resources disposable of Fosun Pharma to create precision medical closed loop, so as to improve health quality and health indicators of the increasing number of patients who suffer from lung cancer at home and abroad."

On the day, Dr. Gao Changqing from the General Hospital of the People's Liberation Army and Dr. Bai Chunxue, Chairman of Chinese Alliance Against Lung Cancer (CAALC) and Chairman of Shanghai Respiratory Research Institute also attended the forum and delivered speeches for the guests on cutting-edge topics such as the future of robotic-assisted surgery and how to prevent and cure lung cancer in the age of internet of things.

Meanwhile, a charitable robotic-assisted pancreatic tumor resection performed with a da Vinci System conducted by Professor Peng Chenghong from Ruijin Hospital was simulcast at the forum. As witnessed by the guests, Professor Peng has successfully performed the surgery on the patient. Later, Mr. Guo Guangchang and Dr. Gary Guthart accompanied by Dr. Shen Baiyong, Vice President of Ruijin Hospital, offered their congratulations to Professor Peng on his success in operation at Ruijin Hospital.

About Shanghai Fosun Pharmaceutical (Group) Co.,Ltd.

Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a leading healthcare Group in the PRC. Fosun Pharma strategically covers important segments of the healthcare industry value-chain, including pharmaceutical manufacturing and R&D, healthcare services, medical diagnosis, medical devices manufacturing and agent, as well as pharmaceutical distribution and retail, making contribution to improving people's health. Fosun Pharma maintains a National Recognized Enterprise Technology Centre and a highly capable international R&D team, focusing on innovation and research of therapeutic areas including cardiovascular system, central nervous system, blood system, metabolism and alimentary system, anti-infection and anti-tumor. With its commitment to innovation for good health and creating a better future, Fosun Pharma will continue insisting on the strategic development approach of "organic growth , external expansion and integrated development", striving to be one of the leading enterprises in the global healthcare market.

The press release is distributed by Wonderful Sky Financial Group on behalf of Fosun Pharmaceutical (Group) Co. Ltd.

For more information, please contact:
Fosun Pharmaceutical (Group) Co. Ltd.
Cathy Wang
Tel: (+86) 021-3398 7122
Fax: (+86) 021-3398 7020
Email: wangpuyu@fosunpharma.com

Wonderful Sky Financial Group Limited
Iris Au Yeung / Cici Liu/ Cherish Xu/ Curry Wang
Tel：(852) 3970 2108 / 3970 2107/ 3757 4715/ 3970 0133
Fax：(852) 2865 1638
Email：po@wsfg.hk / fosunpharma@wsfg.hk